在细胞癌治疗中通过结构修改降低卡博赞提尼布毒性
Jiaxiang Guo1, Xiaotao Yin1, Yongliang Lu1
1Department of Urology, the Fourth Medical Center of PLA General Hospital, Beijing 100853, China.
卡博桑提尼布 (一种氨酸激酶抑制剂) 在细胞癌中显示出有效性,但引起副作用. 这项研究确定了关键的蛋白质标,并建议进行结构修改,以减少毒性,同时保持治疗效益.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- 卡博桑提尼布是一种用于脏细胞癌 (RCC) 的氨酸激酶抑制剂 (TKI).
- 它会引起显著的副作用,包括骨髓抑制,免疫抑制和血管病变.
- 确定有效性和毒性目标对于更安全的治疗至关重要.
研究的目的:
- 确定卡博赞提尼布的关键蛋白标,负责其治疗效果和不良反应.
- 探索卡博赞提尼布的结构修改,以降低毒性,同时保持抗癌疗效.
- 为设计更安全,更有效的RCC技术技能提供基础.
主要方法:
- 一种计算方法选了400个潜在的蛋白质标,使用瑞士标预测和ChemBL.
- 进行了分子对接和结构-活动关系 (SAR) 分析.
- 专注于有助于卡博赞提尼布毒性的结构元素.
主要成果:
- 三种蛋白质被确定为介导抗瘤效应,另外三种与副作用有关.
- 卡博桑提尼布中的甲基组与与毒性相关的蛋白质形成了有害的键.
- 尽量减少这些非目标相互作用可以大幅减少不良影响.
结论:
- 获得了对卡博赞提尼布双重疗效和毒性的结构性见解.
- 提出了TKI设计的优化策略.
- 这项研究为开发更安全,更有效的RCC治疗铺平了道路.
更多相关视频
11:27Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drugs that Stabilize Microtubules
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
